A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result

被引：2

作者：

Chuncharunee, Suporn ^{[1
]}

Kanitsap, Nonglak ^{[2
]}

Suwanban, Tawatchai ^{[3
]}

Khuhapinant, Archrob ^{[4
]}

Uaprasert, Noppacharn ^{[5
]}

Chansung, Kanchana ^{[6
]}

Rattarittamrong, Ekarat ^{[7
]}

Wongkhantee, Somchai ^{[8
]}

Siritanaratanakul, Noppadol ^{[4
]}

Norasetthada, Lalita ^{[7
]}

Nakorn, Thanyaphong Na ^{[5
]}

Charnwiboonsri, Chadchai ^{[9
]}

机构：

[1] Mahidol Univ, Ramathibodi Hosp, Dept Internal Med, Bangkok, Thailand

[2] Thammasat Univ, Dept Internal Med, Pathum Thani, Thailand

[3] Rajavithi Hosp, Dept Internal Med, Bangkok, Thailand

[4] Mahidol Univ, Siriraj Hosp, Dept Med, Bangkok, Thailand

[5] Chulalongkorn Univ, Dept Med, Bangkok, Thailand

[6] Khon Kaen Univ, Dept Internal Med, Khon Kaen, Thailand

[7] Chiang Mai Univ, Dept Internal Med, Chiang Mai, Thailand

[8] Khonkaen Reg Hosp, Dept Internal Med, Khon Kaen, Thailand

[9] Roche Thailand Ltd, Med Dept, Bangkok, Thailand

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.5543.5543

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5543

引用

页数：4

共 50 条

[1] Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients
Bowen, DT
SEMINARS IN ONCOLOGY, 2005, 32 (04) : S16 - S23
[2] A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
Komrokji, Rami S.
Carraway, Hetty E.
Germing, Ulrich
Wermke, Martin
Zeidan, Amer M.
Fu, Eric
Rueter, Bjoern
Burkard, Ute
Osswald, Annika
Foran, James M.
HAEMATOLOGICA, 2022, 107 (11) : 2742 - 2747
[3] A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
Komrokji, Rami S.
Carraway, Hetty E.
Germing, Ulrich
Wermke, Martin
Zeidan, Amer M.
Fu, Eric
Rueter, Bjoern
Burkard, Ute
Osswald, Annika
Foran, James M.
HAEMATOLOGICA, 2022, 107 : 2742 - 2747
[4] Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload
Ivars, David
Teresa Orero, Maria
Javier, Karla
Diaz-Vico, Laura
Luis Garcia-Gimenez, Jose
Mena, Salvador
Tormos, Carmen
Egea, Mercedes
Luis Perez, Pedro
Arrizabalaga, Beatriz
Angeles Ruiz, Maria
Yague, Nuria
Tormo, Mar
Sancho-Tello, Reyes
Gomes, Angela
Alguero, Carmen
Enrique O'Connor, Jose
Saez, Guillermo T.
Carbonell, Felix
Collado, Rosa
CLINICAL BIOCHEMISTRY, 2017, 50 (16-17) : 911 - 917
[5] Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
Garcia-Manero, Guillermo
Jabbour, Elias
Borthakur, Gautam
Faderl, Stefan
Estrov, Zeev
Godley, Lucy
Gabrail, Nashat Y.
Berdeja, Jesus G.
Nadeem, Ahmed
Stein, Karen
Noble, Yvonne
Kassalow, Laurent
Kantarjian, Hagop M.
BLOOD, 2011, 118 (21) : 1628 - 1629
[6] Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure
Jabbour, Elias J.
Garcia-Manero, Guillermo
Strati, Paolo
Mishra, Asmita
Al Ali, Najla H.
Padron, Eric
Lancet, Jeffrey
Kadia, Tapan
Daver, Naval
O'Brien, Susan
Steensma, David P.
Sekeres, Mikkael A.
Gore, Steven D.
Dezern, Amy
Roboz, Gail J.
List, Alan F.
Kantarjian, Hagop M.
Komrokji, Rami S.
CANCER, 2015, 121 (06) : 876 - 882
[7] A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes
Wu, Anfan
List, Alan
Lush, Richard
Bretz, Kelly
Knight, Robert
Lau, Henry
Zeldis, Jerry
BLOOD, 2006, 108 (11) : 299B - 299B
[8] The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
Muzeyyen Aslaner Ak
Birsen Sahip
Ayfer Geduk
Mehmer Ali Ucar
Hacer Kale
Tugba Hacibekiroglu
Merve Gokcen Polat
Yasin Kalpakci
Ali Zahit Bolaman
Birol Guvenc
Sehmus Ertop
Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 299 - 308
[9] Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low-or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium
Short, Nicholas J.
Garcia-Manero, Guillermo
Bravo, Guillermo Montalban
Sasaki, Koji
Sekeres, Mikkael A.
Komrokji, Rami S.
Steensma, David P.
DeZern, Amy E.
Roboz, Gail J.
Kadia, Tapan
Borthakur, Gautam
DiNardo, Courtney
Miller, Darla
Estrov, Zeev
Pemmaraju, Naveen
Daver, Naval
Verstovsek, Srdan
Kantarjian, Hagop M.
Jabbour, Elias
BLOOD, 2015, 126 (23)
[10] The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
Ak, Muzeyyen Aslaner
Sahip, Birsen
Geduk, Ayfer
Ucar, Mehmer Ali
Kale, Hacer
Hacibekiroglu, Tugba
Polat, Merve Gokcen
Kalpakci, Yasin
Bolaman, Ali Zahit
Guvenc, Birol
Ertop, Sehmus
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (02) : 299 - 308

← 1 2 3 4 5 →